NIQ Global Intelligence PLC
Media
NIQ Global Intelligence PLC (NIQ) Stock News
The latest NIQ headlines and market coverage — 5 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.
- The Motley Fool·
Is NIQ Global Intelligence Stock a Buy After Its CEO Purchased Shares Worth $1 Million?
NIQ Global Intelligence CEO James Peck purchased 118,625 shares worth approximately $1 million at $8.43 per share on May 18, 2026, signaling bullish sentiment despite the stock declining 55.5% over the prior year. The company reported strong 11% revenue growth in Q1 2026 but swung to an operating loss due to $64.9 million in restructuring costs. With expectations for $70 million in cost savings this year and a price-to-sales ratio below one, the insider buy suggests confidence in future financial improvement.
- Benzinga·
OMNIQ Reports First Quarter 2026 Financial Results
SALT LAKE CITY, May 20, 2026 (GLOBE NEWSWIRE) -- OMNIQ Corp (OTCMTS: OMQS or "OMNIQ" or "the Company") today announced its financial results for the first quarter 2026. The Company reported $7.7 million in quarterly revenue as well as a gross profit increase of 3.3 percent year over year. The Company continues to implement its product focus and cost-reduction strategy designed to increase revenue & footprint, strengthen profitability, and support long-term operational efficiency. Financial Highlights For the three months ended March 31, 2026, compared to the same period in 2025: Revenue was $7.68 million, compared to $7.98 million in the prior-year period. Gross profit increased to $2.255 million, compared to $2.184 million last year. Loss from operations was ($1.2 million), compared to ($425,000) in the prior-year period. Net loss per share improved to ($0.11), compared to ($0.19) last year. Revenue for the three months ended March 31, 2026, was $7.68 million, compared to $7.98 million for the same period in 2025. While revenue was slightly lower year over year, the Company continued to maintain a strong presence across its core markets and strategic deployments, and at the same time continued implementing products focused on serving end customers Gross profit increased to $2.255 million for the quarter, compared to $2.184 million in the prior year period. The improvement reflects continued focus on operational execution, project mix, and higher-margin opportunities across the business. Loss from operations for the quarter was ($1.2 million), compared to ($425,000) in the first quarter of 2025. Operating results reflected continued investments in technology development, operational infrastructure, and strategic business initiatives designed to support future growth. Net loss per share improved to ($0.11) for the three months ended March 31, 2026, compared to ($0.
- GlobeNewswire Inc.·
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.
- Seeking Alpha·Neutral
NIQ and INTAGE Holdings forge strategic sales partnership